scholarly journals Analysis of Hematopoietic Cell Transplants Using Plasma-Depleted Cord Blood Products That Are Not Red Blood Cell Reduced

2007 ◽  
Vol 13 (11) ◽  
pp. 1346-1357 ◽  
Author(s):  
Robert Chow ◽  
Auayporn Nademanee ◽  
Joseph Rosenthal ◽  
Chatchada Karanes ◽  
Tang-Her Jaing ◽  
...  
Keyword(s):  
Blood Cell ◽  
Cord Blood ◽  
Red Blood Cell ◽  
Hematopoietic Cell ◽  
Blood Products ◽  
Cell Transplants

scholarly journals Optimization of the Aldehyde Dehydrogenase-Based Cord Blood Potency Assay Using Red Blood Cell Depletion

2016 ◽  
Vol 22 (3) ◽  
pp. S424-S425
Author(s):  
Kevin Shoulars ◽  
Tracy Gentry ◽  
Ben Lam ◽  
Bert Wognum ◽  
Steve Szilvassy ◽  
...  
Keyword(s):  
Blood Cell ◽  
Cord Blood ◽  
Aldehyde Dehydrogenase ◽  
Red Blood Cell ◽  
Cell Depletion ◽  
Potency Assay

scholarly journals Nucleated red blood cell in cord blood as a marker of perinatal asphyxia

2013 ◽  
Vol 2 (4) ◽  
pp. 179 ◽  
Author(s):  
Manjusha Goel ◽  
Rashmi Dwivedi ◽  
Poorva Gohiya ◽  
Deeparaj Hegde
Keyword(s):  
Blood Cell ◽  
Cord Blood ◽  
Red Blood Cell ◽  
Perinatal Asphyxia ◽  
Nucleated Red Blood Cell

scholarly journals A SARS-CoV-2-pandémia hatása a vérkészítmény-felhasználásra a Pécsi Tudományegyetemen

2021 ◽  
Vol 162 (43) ◽  
pp. 1717-1723
Author(s):  
Sándor Pál ◽  
Barbara Réger ◽  
Tamás Kiss ◽  
Hussain Alizadeh ◽  
András Vereczkei ◽  
...  
Keyword(s):  
Blood Transfusion ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Blood Product ◽  
Patient Blood Management ◽  
Blood Products ◽  
Blood Management ◽  
Number Of Patients ◽  
Willingness To Donate ◽  
The Impact

Összefoglaló. Bevezetés: A COVID–19-világjárvány betegellátásra gyakorolt hatása hazánkban is jelentős. A vérellátást nehezítette a járványügyi intézkedések következményeként a véradási események elmaradása, a csökkent véradási hajlandóság, továbbá a nehezen megítélhető vérkészítményigény . A „Patient Blood Management” irányelveinek az orvosi gyakorlatban történő egyre szélesebb körű alkalmazása elősegíti az optimális vérkészítmény-felhasználást a transzfúziók lehetőség szerinti elkerülésével. Célkitűzés és módszer: Vizsgálatunk célja a Pécsi Tudományegyetem Klinikai Központjának Janus Pannonius Klinikai Tömbjében a vérkészítmény-felhasználás változásainak felmérése volt a 2020. év első öt hónapjában. Eredmények: A járványügyi intézkedéseket követő időszakban szignifikánsan csökkent a hospitalizált betegeknek (34,08%), a transzfúziót igénylő betegeknek (39,69%) és a felhasznált vörösvérsejt-készítményeknek (46,41%) a száma, valamint az egy betegre jutó felhasznált vörösvérsejt-koncentrátum átlaga (2,61-ről 1,97-re) is. Közel 30%-os arányban csökkent a felhasznált friss fagyasztott plazma egységeinek és a thrombocytakoncentrátumoknak a száma is. Következtetés: A szigorú korlátozások életbe léptetését követően a nehézségek ellenére sikerült elegendő mennyiségű vérkészítményt biztosítani a betegeknek. Az Országos Vérellátó Szolgálat Pécsi Regionális Vérellátó Központja munkatársainak és a klinikusok erőfeszítéseinek köszönhetően a vérkészítményigény és -kínálat között új egyensúly alakult ki, mely megfelelő ellátást biztosított a feltétlenül szükséges transzfúziók kivitelezéséhez. Orv Hetil. 2021; 162(43): 1717–1723. Summary. Introduction: The impact of COVID–19 pandemic on patient care is pronounced also in Hungary. Blood supply was hindered by the reduction of public blood donation events, the reduced willingness to donate, and the difficult predictability of blood product demand as a result of the epidemiological regulations. The wider application of Patient Blood Management guidelines in the medical practice will promote optimal blood product utilization by avoiding transfusions where possible. Objective and method: The aim of our study was to assess the changes in the usage of blood products in the first five months of 2020 at the Clinical Center of the University of Pécs, Janus Pannonius Clinical Building. Results: In the period following the epidemiological measures, we found reduction in the number of hospitalized patients (34.08%), in the number of patients requiring transfusion (39.69%) and in the number of red blood cell products used (46.41%). The number of transfused red blood cell concentrates per patient was also significantly reduced (from 2.61 to 1.97) in this period. The number of transfused fresh frozen plasma units and platelet concentrates also decreased by approximately 30%. Conclusion: After the implementation of the strict restrictions, despite the difficulties, it was possible to provide patients with sufficient blood products. Due to the efforts of both the Regional Blood Transfusion Center of Pécs of the Hungarian National Blood Transfusion Service and of the clinicians, a new balance was established between the demand and the supply of blood products, which provided adequate care for the necessary transfusions. Orv Hetil. 2021; 162(43): 1717–1723.

scholarly journals Inhomogeneities in Alkali-Resistant Hemoglobin. Demonstration of Zone Electrophoretic Differences Using a Cationic Detergent Electrolyte

Blood ◽  
1961 ◽  
Vol 17 (4) ◽  
pp. 409-417 ◽  
Author(s):  
KIRK CONKLIN HOERMAN
Keyword(s):  
Blood Cell ◽  
Cord Blood ◽  
Ammonium Chloride ◽  
Red Blood Cell ◽  
Migration Rates ◽  
Cationic Detergent ◽  
Blood Hemoglobin ◽  
Starch Gels

Abstract Trimethyloctadecyl ammonium chloride, a cationic active detergent electrolyte, when added to starch gels before electrophoresis, caused selected alteration in the migration rates of alkali-resistant hemoglobin. Other red blood cell pigments were not similarly affected. Electrophoretic inhomogeneity of cord blood and thalassemia hemoglobin was noted. New components of cord blood hemoglobin were revealed by the method. A new component in the hemoglobin of cases of severe thalassemia was demonstrated.

scholarly journals Potential Consequences of the Red Blood Cell Storage Lesion on Cardiac Electrophysiology

2020 ◽  
Vol 9 (21) ◽  
Author(s):  
Marissa Reilly ◽  
Chantal D. Bruno ◽  
Tomas M. Prudencio ◽  
Nina Ciccarelli ◽  
Devon Guerrelli ◽  
...  
Keyword(s):  
Stem Cell ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Cardiac Electrophysiology ◽  
Pluripotent Stem Cell ◽  
Induced Pluripotent Stem Cell ◽  
Cardiac Complications ◽  
Blood Products ◽  
Storage Lesion ◽  
Induced Pluripotent

Background The red blood cell (RBC) storage lesion is a series of morphological, functional, and metabolic changes that RBCs undergo following collection, processing, and refrigerated storage for clinical use. Since the biochemical attributes of the RBC unit shifts with time, transfusion of older blood products may contribute to cardiac complications, including hyperkalemia and cardiac arrest. We measured the direct effect of storage age on cardiac electrophysiology and compared it with hyperkalemia, a prominent biomarker of storage lesion severity. Methods and Results Donor RBCs were processed using standard blood‐banking techniques. The supernatant was collected from RBC units, 7 to 50 days after donor collection, for evaluation using Langendorff‐heart preparations (rat) or human induced pluripotent stem cell–derived cardiomyocytes. Cardiac parameters remained stable following exposure to “fresh” supernatant from red blood cell units (day 7: 5.8±0.2 mM K + ), but older blood products (day 40: 9.3±0.3 mM K + ) caused bradycardia (baseline: 279±5 versus day 40: 216±18 beats per minute), delayed sinus node recovery (baseline: 243±8 versus day 40: 354±23 ms), and increased the effective refractory period of the atrioventricular node (baseline: 77±2 versus day 40: 93±7 ms) and ventricle (baseline: 50±3 versus day 40: 98±10 ms) in perfused hearts. Beating rate was also slowed in human induced pluripotent stem cell–derived cardiomyocytes after exposure to older supernatant from red blood cell units (−75±9%, day 40 versus control). Similar effects on automaticity and electrical conduction were observed with hyperkalemia (10–12 mM K + ). Conclusions This is the first study to demonstrate that “older” blood products directly impact cardiac electrophysiology, using experimental models. These effects are likely caused by biochemical alterations in the supernatant from red blood cell units that occur over time, including, but not limited to hyperkalemia. Patients receiving large volume and/or rapid transfusions may be sensitive to these effects.

Transfusion Requirements in Nonmyeloablative Allogeneic Stem Cell Transplantation for Hematologic Malignancies.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4178-4178
Author(s):  
Jason W. Brown ◽  
Darrell J. Triulzi
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Platelet Transfusion ◽  
Transfusion Requirement ◽  
Hematologic Malignancies ◽  
Packed Red Blood Cells ◽  
Transfusion Requirements ◽  
Cell Transplants

Abstract Nonmyeloablative allogeneic stem cell transplants (NM-ASCT) are increasingly being utilized to treat hematologic malignancies in settings where high dose, fully ablative regimens would not be tolerated. We identified 10 male and 13 female patients (n=23) ranging in age from 19 to 63 years old (mean=48) representing all patients whom had undergone NM-ASCT in the last five years. NM-ASCT were performed for acute myelogenous leukemia (n=7), non-Hodgkin’s lymphoma (n=6), Hodgkin’s disease (n=4), multiple myeloma (n=3), myelodysplastic syndrome (n=2), and acute lymphoblastic leukemia (n=1). The majority of patients had undergone at least one previous stem cell transplant (n=16). The mean number of stem cells infused per kilogram at time of transplant was 4.72 X 106 ±1.97 X 106 stem cells and mean time to engraftment was 15.8 ±5.15 days (3 consecutive days with ANC >500). All of the subjects required both platelet and red cell transfusion during the period of analysis. Mean transfusion requirements in the 7 days prior to transplantation were 3.1 ±5.9 units of platelets and 1.2 ±1.5 units of packed red blood cells. Mean platelet transfusion requirements 90 days post transplant were 73.7 ±79.7 units and mean red cell requirements 11.6 ±8.3 units. Total mean transfusion requirements during the time period analyzed were 76.9 ±82.2 units of platelets and 12.8 ±8.9 units of packed red blood cells. There was no significant correlation between the number of stem cells infused per kilogram on day of transplant, the number of previous transplants, or the time to engraftment with red blood cell or platelet transfusion requirements. Our data illustrate a higher proportion of patients requiring platelet transfusions (100% vs. 23%) and red blood cell transfusions (100% vs. 63%) as well as a higher platelet transfusion requirement (median 48 vs. 0 units) and packed red blood cell transfusion requirement (median 11 vs. 2 units) than other authors have reported in a 60 day period in HLA-matched sibling NM-ASCT [Weissinger et al. Blood 98(13):3584-8, 2001]. As is illustrated by the percentage of patients undergoing previous fully ablative stem cell transplants, our patients represent a heavily pretreated population and this may account for the higher transfusion requirements seen in this analysis. Although patients undergoing NM-ASCT receive reduced intensity therapy, in our analysis their transfusion requirements remain substantial.

Sign in / Sign up

Export Citation Format

Share Document